Male Hypogonadism Pipeline Review, H1 2019 - ResearchAndMarkets.com
The "Male Hypogonadism - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Male
Hypogonadism - Pipeline Review, H1 2019" drug pipelines has
been added to ResearchAndMarkets.com's offering.
Male Hypogonadism - Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Male Hypogonadism
(Male Health), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.
The Male Hypogonadism (Male Health) pipeline guide also reviews of key
players involved in therapeutic development for Male Hypogonadism and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and
Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the
Universities portfolio in Phase II stages comprises 1 molecules,
respectively.
Male Hypogonadism (Male Health) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Male Hypogonadism - Overview
- Male Hypogonadism - Therapeutics Development
- Male Hypogonadism - Therapeutics Assessment
- Male Hypogonadism - Companies Involved in Therapeutics Development
- Male Hypogonadism - Drug Profiles
- Male Hypogonadism - Dormant Projects
- Male Hypogonadism - Discontinued Products
- Male Hypogonadism - Product Development Milestones
- Appendix
Companies Mentioned
- Allergan Plc
- Clarus Therapeutics Inc
- Diurnal Group Plc
- EndoCeutics Inc
- Ferring International Center SA
- Lipocine Inc
- M et P Pharma AG
- Medlab Clinical Ltd
- Merck & Co Inc
- Mereo Biopharma Group Plc
- TesoRx Pharma LLC
- Viramal Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5hyt7v
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005701/en/